Antimicrobial therapy of Staphylococcus aureus bloodstream infection

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Staphylococcus aureus bloodstream infection (BSI) is a major cause of patient morbidity and mortality.
• Methicillin-susceptible S. aureus BSI is optimally treated with penicillins.
• Methicillin-resistant S. aureus (MRSA) is increasingly prevalent in hospital-acquired BSIs.

Purpose of the Study:

• To review current therapeutic options for Staphylococcus aureus bloodstream infections.
• To summarize evidence on the efficacy and challenges of treating MRSA BSI.
• To discuss emerging drugs for MRSA infections.

Main Methods:

• Literature review of published data on S. aureus BSI treatment.
• Analysis of clinical experience with various antimicrobial agents.
• Evaluation of evidence for current and novel therapeutic strategies.

Main Results:

• Penicillins are the established treatment for methicillin-susceptible S. aureus BSI.
• Glycopeptides are standard for MRSA BSI, but clinical failures and reduced susceptibility are concerns.
• Newer agents for MRSA infections lack established efficacy data for BSI.

Conclusions:

• Optimal treatment for S. aureus BSI depends on methicillin susceptibility.
• Challenges in MRSA BSI treatment include vancomycin failures and monitoring difficulties.
• Further evidence is needed for novel MRSA therapies in bloodstream infections.